1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

ASCO Data Support Roche’s Grand Plan For Non-Stop Avastin Treatment

 
• By Emily Hayes and Mary Jo Laffler

After the loss of the breast cancer indication for Avastin, Roche looks to long-term treatment in colon cancer as growth driver. And fourth Phase III study of Avastin in ovarian cancer proves positive as the drug makes commercial headway in European markets where it is approved for this indication.

CHICAGO––Roche/Genentech Inc. is emerging from the American Society of Clinical Oncology annual meeting with some extremely valuable data in hand – not only a breakthrough breast cancer therapy with the antibody-drug conjugate T-DM1 and another study moving the company closer to establishing its blockbuster Avastin in another cancer setting, but a study in the original Avastin indication of colon cancer that shows the value of continuous treatment. But that progress puts Roche in the position of grappling with difficult cost issues.

Priced at $4,900 per month, Avastin (bevicizumab) is already a common target for complaints about the high costs of oncologics....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pharma Companies Suspecting Clinical Trial Fraud Should Move Quickly, Quietly

 
• By Sue Sutter

Sponsors should investigate signals of possible fraud in a manner that does not raise alarms or else evidence might disappear, UK and US regulators said.

Swissmedic Launches Pilot To Expedite Clinical Trial Applications

 
• By Anabel Costa-Ferreira

Swiss health care products agency Swissmedic will launch a pilot in July to fast track clinical trial applications, which the agency claims will place Switzerland at the forefront compared to other European countries.

EU Countries Rally Behind Novel Pathway For Combined Drug/IVD Trials

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

More from R&D

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 
• By Michael McCaughan

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.